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Valdecoxib [systematic name: 4-(5-methyl-3-phenylisoxazol-4-
yl)benzenesulfonamide], C16H14N2O3S, a diaryl-substituted
isoxazole, is a non-steroidal anti-in¯ammatory drug (NSAID)
that is used for the treatment of rheumatoid arthritis,
osteoarthritis and dysmenorrhea pain. The planar isoxazole
ring is oriented at angles of 22.2 (1) and 54.3 (1) with respect
to the phenyl and benzenesulfonamide groups, respectively.
NÐH  O and CÐH  O hydrogen bonds and NÐH  ,
CÐH   and ± interactions stabilize the crystal packing.
Comment
Valdecoxib, whose brand name is Bextra, is a nonsteroidal
anti-in¯ammatory drug (NSAID) that is used for the treat-
ment of osteoarthritis or rheumatoid arthritis and for the
treatment of primary dysmenorrhea (Scheen & Malaise,
2004). Valdecoxib is a potent and speci®c inhibitor of cyclo-
oxygenase-2 (COX-2), an isoform of cyclo-oxygenase which is
the key enzyme catalysing the inversion of arachidonic acid
into prostaglandins and thromboxane (Coats et al., 2004).
COX-2 is an inducible enzyme that is primarily found in
in¯ammatory cells and tissues and so the inhibition of this
enzyme by valdecoxib does not affect the normal cells (Gierse
et al., 1996). Valdecoxib is a diaryl-substituted isoxazole that
exhibits analgesic and antipyretic properties in addition to
anti-in¯ammatory properties in animal models. These COX-2-
selective diarylheterocyclic inhibitors have been reported to
be a reversible competitive inhibitor of COX-1 while
demonstrating time-dependent irreversible inhibition of
COX-2, which accounts for the potency and selectivity
demonstrated by members of this structural class (Walkeri et
al., 2001). The phenylsulphonamide moiety of the diaryl-
heterocycles associate within a side pocket present in the
active site of COX-2, and this pocket is more accessible in
COX-2 than in COX-1, which is the result of the substitution
of valine for isoleucine at position 523 in COX-1 (Kurumbail et
al., 1996).
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In the title molecule, (I) (Fig. 1), the isoxzaole ring (A) is
planar and forms dihedral angles of 54.3 (1) and 22.2 (1) with
the planes through the B (C6±C11) and C (C16±C21) benzene
rings, respectively. The S atom in the sulphonamide group has
sp3 hybridization. Atom N15 forms an NÐH  O hydrogen
bond with atom O13i [symmetry code: (i) 32 ÿ x, 12 + y, z],
forming chains along the b axis (Fig. 2). An NÐH   inter-
action between atom N15 and ring C of the symmetry-related
molecule at (2 ÿ x, y ÿ 12, 12 ÿ z) occurs, with an N  centroid
(Cg) distance of 3.429 (4) AÊ . The isoxazole rings of the
inversion-related molecules at (x, y, z) and (2 ÿ x, 1 ÿ y,
1 ÿ z) interact via face-to-face ± interaction, the Cg  Cg
distance being 3.606 (2) AÊ (Fig. 3). In addition to the above
interactions, the molecular packing in the crystal structure is
further stabilized by a number of weak CÐH  O and CÐ
H   interactions (Table 1; Cg1, Cg2 and Cg3 denote the
centroids of rings A, B and C, respectively).
Experimental
Deoxybenzoin (0.01 M) was treated with hydroxylamine hydro-
chloride (0.01 M) in the presence of sodium acetate to produce the
corresponding oxime. When the oxime was deprotonated using n-
butyllithium (2 equivalents) and condensed with ethyl acetate (25 ml)
the corresponding isoxazoline was produced. Chlorosulfonic acid
(0.01 M) treatment followed by addition of sulfonyl chloride
(0.01 M) with aqueous ammonia to the isoxazoline yielded valde-
coxib.
Crystal data
C16H14N2O3S
Mr = 314.35
Orthorhombic, Pbca
a = 12.872 (2) AÊ
b = 9.282 (3) AÊ
c = 24.761 (7) AÊ
V = 2958.4 (14) AÊ 3
Z = 8
Dx = 1.412 Mg m
ÿ3
Mo K radiation
Cell parameters from 25 re¯ections
 = 8±15
 = 0.23 mmÿ1
T = 293 (2) K
Rectangular block, colourless
0.35  0.30  0.20 mm
Data collection
Enraf±Nonius CAD-4
diffractometer
Non±pro®led !/2 scans
4295 measured re¯ections
4295 independent re¯ections
2167 re¯ections with I > 2(I)
max = 30.0

h = 0! 18
k = 0! 13
l = ÿ34! 0
3 standard re¯ections
every 120 min
intensity decay: none
Refinement
Re®nement on F 2
R[F 2 > 2(F 2)] = 0.055
wR(F 2) = 0.179
S = 1.03
4295 re¯ections
208 parameters
H atoms treated by a mixture of
independent and constrained
re®nement
w = 1/[2(Fo
2) + (0.0714P)2
+ 1.6196P]
where P = (Fo
2 + 2Fc
2)/3
(/)max = 0.002
max = 0.32 e AÊ
ÿ3
min = ÿ0.35 e AÊ ÿ3
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Figure 1
ORTEP-3 (Farrugia, 1997) plot of the title compound, showing 30%
probability displacement ellipsoids and the atom-numbering scheme.
Figure 2
Packing diagram of the molecules, viewed down the b axis. Dotted lines
indicate the NÐH  O hydrogen bond between atoms N15 and O13.
Figure 3
A view, down the a axis, of the NÐH  , CÐH   and   
interactions (dashed lines).
Table 1
Hydrogen-bond geometry (AÊ , ).
DÐH  A DÐH H  A D  A DÐH  A
N15ÐH15A  O13i 0.90 (1) 2.12 (3) 3.010 (4) 168 (2)
N15ÐH15B  Cg3ii 0.90 (1) 2.59 (3) 3.429 (4) 156 (2)
C7ÐH7  N2iii 0.93 2.82 3.429 (5) 124
C8ÐH8  O1iv 0.93 2.82 3.529 (4) 134
C11ÐH11  O13v 0.93 2.65 3.383 (4) 136
C17ÐH17  O14i 0.93 2.61 3.273 (4) 128
C18ÐH18  O14i 0.93 2.84 3.387 (5) 119
C18ÐH18  O13vi 0.93 2.61 3.389 (5) 142
C19ÐH19  Cg2vi 0.93 3.10 3.708 (4) 125
C21ÐH21  Cg1vii 0.93 2.88 3.631 (4) 138
C22ÐH22A  Cg3iii 0.96 2.74 3.637 (4) 157
Symmetry codes: (i) ÿx 32; y 12; z; (ii) ÿx  2; yÿ 12;ÿz 12; (iii)ÿx 2;ÿy 1;ÿz 1; (iv) xÿ 12;ÿy 12;ÿz 1; (v) ÿx 2; y  12;ÿz 12; (vi)
x; y 1; z; (vii) ÿx 52; y 12; z. Cg1, Cg2 and Cg3 denote the centroids of rings A, B
and C, respectively.
Amine H atoms were located in a difference Fourier map and were
re®ned isotropically, with an NÐH distance restraint of 0.90 (1) AÊ .
The remaining H atoms were placed in idealized positions (CÐ
Haromatic = 0.93 AÊ and CÐHmethyl = 0.96 AÊ ) and allowed to ride on
their parent atoms, with Uiso(H) = 1.2Ueq(C) or 1.5Ueq(Cmethyl).
Data collection: CAD-4 EXPRESS (Enraf±Nonius, 1994); cell
re®nement: CAD-4 EXPRESS; data reduction: XCAD4 (Harms &
Wocadlo, 1995); program(s) used to solve structure: SHELXS97
(Sheldrick, 1997); program(s) used to re®ne structure: SHELXL97
(Sheldrick, 1997); molecular graphics: PLATON (Spek, 2003) and
ORTEP-3 (Farrugia, 1997); software used to prepare material for
publication: SHELXL97.
SMMS acknowledges the Council of Scienti®c and Indus-
trial Research for ®nancial support.
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